India, Oct. 9 -- Lupin announced the launch of a strategic partnership program aimed at expanding the reach of PrecisionSphere' - the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi B.V. (Nanomi). PrecisionSphere' demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent United States Food and Drug Administration's (U.S. FDA) approval for the first product developed with this platform.Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles, whether in development or already on the market, especially those that could benefit from longer-acting formulations.
Published by HT Digital Content Services with p...